Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer

- National Quality Strategy Domain: Effective Clinical Care
- Meaningful Measure Area: Appropriate Use of Healthcare

2019 COLLECTION TYPE:

MIPS CLINICAL QUALITY MEASURES (CQMS)

MEASURE TYPE:

Process

DESCRIPTION:

The percentage of clinically node negative (clinical stage T1N0M0 or T2N0M0) breast cancer patients before or after neoadjuvant systemic therapy, who undergo a sentinel lymph node (SLN) procedure

INSTRUCTIONS:

This measure is to be submitted <u>each time</u> a procedure is performed during the performance period for patients age 18 years and older who are operated upon for invasive breast cancer that are clinically node negative (clinical stage T1N0M0 or T2N0M0) before or after neoadjuvant systemic therapy. This measure may be submitted by Merit-based Incentive Payment System (MIPS) eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.

Measure Submission Type:

Measure data may be submitted by individual MIPS eligible clinicians, groups, or third party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

DENOMINATOR:

Patients aged 18 and older with primary invasive breast cancer

Denominator Criteria (Eligible Cases):

Patients aged 18 and older at date of encounter

AND

Diagnosis for Female/Male Breast Cancer (ICD-10-CM): C50.011, C50.012, C50.019, C50.021, C50.022, C50.029, C50.111, C50.112, C50.119, C50.121, C50.122, C50.129, C50.211, C50.212, C50.219, C50.221, C50.222, C50.229, C50.311, C50.312, C50.319, C50.321, C50.322, C50.329, C50.411, C50.412, C50.419, C50.421, C50.422, C50.429, C50.511, C50.512, C50.519, C50.521, C50.522, C50.529, C50.611, C50.612, C50.619, C50.621, C50.622, C50.629, C50.811, C50.812, C50.819, C50.821, C50.822, C50.829, C50.911, C50.912, C50.919, C50.921, C50.929

<u>AND</u>

Patient encounter during the performance period (CPT): 19301, 19302, 19307, 38500, 38510, 38520, 38525, 38530, 38542, 38740, 38745, 38900

AND

Clinically Node Negative (T1N0M0 or T2N0M0) Invasive Breast Cancer Before or After Neoadjuvant Systemic Therapy: G9911

NUMERATOR:

Patients who undergo a SLN procedure

Numerator Options:

Performance Met: Sentinel lymph node biopsy procedure performed (G8878)

<u>OR</u>

Denominator Exception: Documentation of reason(s) sentinel lymph node biopsy

not performed (e.g., reasons could include but not limited to; non-invasive cancer, incidental discovery of breast cancer on prophylactic mastectomy, incidental discovery of breast cancer on reduction mammoplasty, preoperative biopsy proven lymph node (LN) metastases, inflammatory carcinoma, stage 3 locally advanced cancer, recurrent invasive breast cancer, clinically node positive after neoadjuvant systemic therapy, patient refusal after informed consent, patient with significant age, comorbidities, or limited life expectancy and favorable tumor; adjuvant systemic therapy unlikely to

change) (G8880)

<u>OR</u>

Performance Not Met: Sentinel lymph node biopsy procedure not performed,

reason not given (G8882)

RATIONALE:

A sentinel lymph node (SLN) procedure is defined as a method of axillary or other regional lymph node assessment that requires either a radioisotope and/or blue dye injection in the breast with subsequent identification of radioactive or blue stained node(s) in the axilla or other lymph node basin. There is level one evidence that breast cancer SLN biopsy is as accurate as axillary dissection for breast cancer staging and is associated with less morbidity than routine axillary dissection.

CLINICAL RECOMMENDATION STATEMENTS:


The current body of reported surgical experience shows that SLN biopsy is suitable for virtually all clinically nodenegative T1-2 invasive breast cancers. (The American Society of Breast Surgeons, 2010)

COPYRIGHT:

This measure is owned by The American Society of Breast Surgeons.

THESE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

2019 Clinical Quality Measure Flow for Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer



Data Completeness = Performance Met (a=40 procedures) + Denominator Exception (b=10 procedures) + Performance Not Met (c=2 -procedures) = 70 procedures = 87.50% Eligible Population / Denominator (d=80 procedures) = 80 procedures Performance Rate= Performance Met (a=40 procedures) = 40 procedures = 66.67% Data Completeness Numerator (70 procedures) - Denominator Exception (b=10 procedures) = 60 procedures

NOTE: Submission Frequency: Procedure

^{*}See the posted Measure Specification for specific coding and instructions to submit this measure.

2019 Clinical Quality Measure Flow Narrative for Quality ID #264: Sentinel Lymph Node Biopsy for Invasive Breast Cancer

Please refer to the specific section of the Measure Specification to identify the denominator and numerator information for use in submitting this Individual Specification.

- 1. Start with Denominator
- 2. Check Patient Age:
 - a. If Patient Age is greater than or equal to 18 Years on Date of Service equals No during the measurement period, do not include in Eligible Population. Stop Processing.
 - b. If Patient Age is greater than or equal to 18 Years on Date of Service and equals Yes during the measurement period, proceed to check Patient Diagnosis.
- 3. Check Patient Diagnosis:
 - a. If Diagnosis of Female/Male Breast Cancer as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
 - b. If Diagnosis of Female/Male Breast Cancer as Listed in the Denominator equals Yes, proceed to check Encounter Performed.
- 4. Check Encounter Performed:
 - a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
 - b. If Encounter as Listed in the Denominator equals Yes, proceed to check Clinically Node Negative (T1N0M0 or T2N0M0) Invasive Breast Cancer Before or After Neoadjuvant Systemic Therapy.
- 5. Check Clinically Node Negative (T1N0M0 or T2N0M0) Invasive Breast Cancer Before or After Neoadjuvant Systemic Therapy:
 - a. If Clinically Node Negative (T1N0M0 or T2N0M0) Invasive Breast Cancer Before or After Neoadjuvant Systemic Therapy equals No, do not include in Eligible Population. Stop Processing.
 - b. If Clinically Node Negative (T1N0M0 or T2N0M0) Invasive Breast Cancer Before or After Neoadjuvant Systemic Therapy equals Yes, include in Eligible Population.
- 6. Denominator Population:
 - a. Denominator Population is all Eligible Procedures in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 procedures in the Sample Calculation.
- 7. Start Numerator
- 8. Check Sentinel Lymph Node Biopsy Procedure Performed:
 - a. If Sentinel Lymph Node Biopsy Procedure Performed equals Yes, include in Data Completeness Met and Performance Met.
 - b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 procedures in the Sample Calculation.

- c. If Sentinel Lymph Node Biopsy Procedure Performed equals No, proceed to check Documentation of Reason(s) Sentinel Lymph Node Biopsy Not Performed.
- 9. Check Documentation of Reason(s) Sentinel Lymph Node Biopsy Not Performed:
 - a. If Documentation of Reason(s) Sentinel Lymph Node Biopsy Not Performed equals Yes, include in Data Completeness Met and Denominator Exception.
 - b. Data Completeness Met and Denominator Exception letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter b equals 10 procedures in the Sample Calculation.
 - c. If Documentation of Reason(s) Sentinel Lymph Node Biopsy Not Performed equals No, proceed to check Sentinel Lymph Node Biopsy Procedure Not Performed, Reason Not Given.
- 10. Check Sentinel Lymph Node Biopsy Procedure Not Performed, Reason Not Given:
 - a. If Sentinel Lymph Node Biopsy Procedure Not Performed, Reason Not Given equals Yes, include in the Data Completeness Met and Performance Not Met.
 - b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 20 procedures in the Sample Calculation.
 - c. If Sentinel Lymph Node Biopsy Procedure Not Performed, Reason Not Given equals No, proceed to check Data Completeness Not Met.
- 11. Check Data Completeness Not Met:
 - a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 procedures have been subtracted from Data Completeness Numerator in the Sample Calculation.

SAMPLE CALCULATIONS: Data Completeness = Performance Met (a=40 procedures) + Denominator Exception (b=10 procedures) + Performance Not Met (c=2 -procedures) = 70 procedures = 87.50% Eligible Population / Denominator (d=80 procedures) = 80 procedures Performance Rate= Performance Met (a=40 procedures) = 40 procedures = 66.67% = 60 procedures = 60 procedures